PR Newswire All News ReleasesCodex · 实盘不做把握 7/10不做原因:无增量信息
北京时间·🕒 发布 16:16:00·⟳ 抓取 16:16:19 +19s·⚡ 决策 08-27 16:40:20 +24m01s·61.1 天前
SBS再次提醒Replimune投资者参与证券欺诈集体诉讼，未披露新增诉讼事实
本次PR Newswire稿件相当于重复的诉讼参与提醒，真正的股价与基本面冲击已在2026-04-10 FDA CRL及后续诉讼披露中释放；2026-08-27未出现可改变短线方向或价格的新事实。
📄 原文PR Newswire All News Releases↗ 原文
REPL Investors Have Opportunity to Lead Replimune Group, Inc. Securities Fraud Lawsuit with SBS Law
LOS ANGELES, Aug. 27, 2026 /PRNewswire/ -- Schall, Brown & Schwartz LLP ("SBS"), a national shareholder rights litigati…
不做 Replimune Group, Inc.（REPL.US）
不做Replimune Group, Inc.（REPL.US）：本次只是既有证券诉讼的重复律师征集提醒，核心FDA CRL利空和诉讼事实已在4月及8月中旬传播，且未新增判决、监管处罚、赔偿金额或经营损害，不满足强空开仓红线。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
结论摘要
事件正文只说明投资者可在2026-10-05前申请担任Replimune证券欺诈案首席原告，诉讼事实沿用4月FDA CRL与研究设计缺陷指控；公开检索显示SBS同稿已在8月18日出现、其他律所8月25日也已扩散，且公司8月6日已宣布RP1相关产品获FDA加速批准，因此本条对Replimune Group, Inc.（REPL.US）不是新的强空催化，不开仓。
消息传播链
- Replimune披露FDA就RP1 BLA发出第二次Complete Response Letter，这是诉讼指控的核心历史事实。市场反应:诉讼材料称REPL在4月10日和4月13日已大幅下跌。
- SBS已发布与本次高度相同的Replimune诉讼提醒，说明8月27日不是首次出现。
- 其他律所也发布同一诉讼的投资者提醒，事件已扩散。
- 本次待研判稿件是SBS再次提醒投资者参与诉讼，未披露新的判决、金额或监管进展。
关键理由
- 本次没有新增判决、SEC执法、罚款、赔偿估计或业务停摆，只是律师事务所重复征集首席原告。
- 同一诉讼提醒至少在2026-08-18已由SBS发布，2026-08-25又有其他律所发布，传播不新鲜。
- 公司在2026-08-06宣布TUDRIQEV获FDA加速批准，削弱了把4月CRL旧事实作为当前强空交易催化的力度。
主要风险
- 证券诉讼若后续进入实质赔偿、和解或出现监管重新介入，可能重新构成负面催化。
- 无法调用内部行情工具验证实时盘前报价；本结论不依赖精确入场价，因为没有给出ENTER。
反向证据
- 做空前查反向 · 来源 web · 日期 2026-08-06 · 影响 weakens
公司8月6日公告RP1相关TUDRIQEV获FDA加速批准，且公开披露显示SEC调查6月24日结束且不建议执法，削弱把本次律师提醒作为强空的依据。
检索:Replimune August 2026 FDA approval RP1 TUDRIQEV lawsuit SEC investigation no enforcement 原文 ↗ - 做空前查反向 · 来源 web · 日期 2026-08-18 · 影响 weakens
同一SBS诉讼提醒已在8月18日出现，本次8月27日不是新首发。
检索:Replimune securities fraud lawsuit August 18 2026 SBS Law 原文 ↗
先例如何影响了这次决策
对本次决策的影响:先例不足未改变结论；重复传播与无新增损害事实是主要AVOID依据。
方向:律师事务所重复发布证券集体诉讼征集提醒通常不是新的公司基本面事件；本次不以外部先例定方向。
涨幅量级:没有足够同市场、同机制且首发锚点干净的先例用于校准幅度；且本次结论是不做，不需要设置tp/sl。
形态:当前证据更像旧利空重复传播，而不是新诉讼冲击；公开传播链已足以判定无新增edge。
原文全文
展开原文 · 2,772 字
REPL Investors Have Opportunity to Lead Replimune Group, Inc. Securities Fraud Lawsuit with SBS Law
LOS ANGELES, Aug. 27, 2026 /PRNewswire/ -- Schall, Brown & Schwartz LLP ("SBS"), a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Replimune Group, Inc. ("Replimune" or "the Company") (NASDAQ: REPL) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Shareholders who purchased shares of REPL during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointments. Appointment as lead plaintiff is not required to partake in any recovery.
CLASS PERIOD: October 20, 2025 to April 10, 2026
DEADLINE: October 5, 2026
If you are a shareholder who suffered a loss, click here to participate.
CASE DETAILS: According to the Complaint, the Company made false and misleading statements to the market. Replimune failed to address study design concerns the FDA had previously communicated about its Biologics License Application ("BLA"). The Company submitted data from an unplanned analysis of the RP1-104 study to the FDA which included only 10% of the planned study enrollment. Due to these actions, the FDA was likely to reject the Company's BLA. Based on these facts, the Company's public statements were false and materially misleading throughout the class period. When the market learned the truth about Replimune, investors suffered damages.
We also encourage you to contact Brian Schall or David Schwartz of Schall, Brown & Schwartz LLP, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at [email protected].
The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.
Join the case to recover your losses
WHY SBS? Schall, Brown & Schwartz LLP represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation. Bringing together the extensive experience and diverse skillsets of founding partners Brian Schall, Andrew Brown, and David Schwartz, SBS is dedicated to aggressively advocating for every investor.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.
CONTACT:
Schall, Brown & Schwartz LLP
Brian Schall, Esq.,
Andrew Brown, Esq.,
David Schwartz, Esq.,
www.schallfirm.com
Office: 310-301-3335
[email protected]
SOURCE Schall, Brown & Schwartz LLP
LOS ANGELES, Aug. 27, 2026 /PRNewswire/ -- Schall, Brown & Schwartz LLP ("SBS"), a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Replimune Group, Inc. ("Replimune" or "the Company") (NASDAQ: REPL) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Shareholders who purchased shares of REPL during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointments. Appointment as lead plaintiff is not required to partake in any recovery.
CLASS PERIOD: October 20, 2025 to April 10, 2026
DEADLINE: October 5, 2026
If you are a shareholder who suffered a loss, click here to participate.
CASE DETAILS: According to the Complaint, the Company made false and misleading statements to the market. Replimune failed to address study design concerns the FDA had previously communicated about its Biologics License Application ("BLA"). The Company submitted data from an unplanned analysis of the RP1-104 study to the FDA which included only 10% of the planned study enrollment. Due to these actions, the FDA was likely to reject the Company's BLA. Based on these facts, the Company's public statements were false and materially misleading throughout the class period. When the market learned the truth about Replimune, investors suffered damages.
We also encourage you to contact Brian Schall or David Schwartz of Schall, Brown & Schwartz LLP, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at [email protected].
The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.
Join the case to recover your losses
WHY SBS? Schall, Brown & Schwartz LLP represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation. Bringing together the extensive experience and diverse skillsets of founding partners Brian Schall, Andrew Brown, and David Schwartz, SBS is dedicated to aggressively advocating for every investor.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.
CONTACT:
Schall, Brown & Schwartz LLP
Brian Schall, Esq.,
Andrew Brown, Esq.,
David Schwartz, Esq.,
www.schallfirm.com
Office: 310-301-3335
[email protected]
SOURCE Schall, Brown & Schwartz LLP
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。